Recursion Pharmaceuticals Inc Cash Flow-to-Debt Ratio
Recursion Pharmaceuticals Inc cash flow-to-debt ratio. Recursion Pharmaceuticals Inc (RXRX) has a Cash Flow-to-Debt Ratio of -0.36x as of June 2026, meaning its operating cash flow of $-105.95 Million could theoretically repay 0% of its total liabilities ($297.67 Million) in one year. See RXRX financial flexibility index to measure the company's free cash flow as a share of total liabilities.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of Recursion Pharmaceuticals Inc (2019–2025)
Cash flow-to-debt ratio of Recursion Pharmaceuticals Inc from 2019 to 2025. Historical debt coverage capacity for Recursion Pharmaceuticals Inc across 7 annual periods. Check Recursion Pharmaceuticals Inc cash flow reinvestment rate to assess the company's total reinvestment commitment from operating cash flow.
Recursion Pharmaceuticals Inc Cash Flow-to-Debt Ratio by Year (2019–2025)
Recursion Pharmaceuticals Inc cash flow-to-debt ratio by year from 2019 to 2025. Year-by-year debt coverage analysis for Recursion Pharmaceuticals Inc. For the full cash flow conversion analysis, see Recursion Pharmaceuticals Inc operating cash flow efficiency.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2025 | -1.08x | $-371.81 Million | $343.26 Million | ▼ -24.8% |
| 2024 | -0.87x | $-359.17 Million | $413.82 Million | ▲ +42.6% |
| 2023 | -1.51x | $-287.78 Million | $190.26 Million | ▼ -290.2% |
| 2022 | -0.39x | $-83.52 Million | $215.48 Million | ▲ +83.5% |
| 2021 | -2.35x | $-158.61 Million | $67.41 Million | ▼ -2516.8% |
| 2020 | -0.09x | $-45.40 Million | $504.87 Million | ▲ +64.4% |
| 2019 | -0.25x | $-57.04 Million | $225.70 Million | — |